



AVITA MEDICAL, INC. (ASX:AVH)

Results of Annual General Meeting

Valencia, Calif., USA, 5 June 2024 and Melbourne, Australia, 6 June 2024: In accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, we advise the outcome in respect of each of the resolutions put to the meeting of AVITA Medical, Inc.'s stockholders on June 5, 2024 (United States) / June 6, 2024 (Australia) in the attached voting results summary.

Authorized for release by the General Counsel & Corporate Secretary of AVITA Medical, Inc.

About AVITA Medical, Inc.

AVITA Medical® is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient's own skin to create Spray-On Skin™ Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, in the United States.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, has received CE-mark approval in Europe and has PMDA approval in Japan. To learn more, visit www.avitamedical.com.

Forward-Looking Statements

Statements in this announcement may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as "anticipate," "expect," "intend," "could," "may," "will," "believe," "estimate," "look forward," "forecast," "goal," "target," "project," "continue," "outlook," "guidance," "future," and similar words or expressions, and the use of future dates. Forward-looking statements in this announcement include but are not limited to statements concerning our product development activities, regulatory approval of our products, the potential for future growth of our business, and our ability to achieve financial goals. These statements are made as of the date of this announcement, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the "Risk Factors" section of the Company's latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.

###

AVITA Medical, Inc.
Annual Meeting of Shareholders
June 5, 2024 (United States) / June 6, 2024 (Australia)
Voting Results

The following information is provided for the purposes of ASX Listing Rule 3.13.2.

Resolution details	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll			Resolution result
Resolution	For	Against	Proxy's discretion	Abstain	For	Against	Abstain*	Carried / not carried
Resolution 1: Election of Directors to serve a one-year term Louis Panaccio, Non-Executive Chairman of the Board of Directors	9,639,179 73.71%	0 0%	0 0%	3,437,336 26.29%	9,639,179 73.71%	0 0%	3,437,336 26.29%	Carried
Resolution 1: Election of Directors to serve a one-year term James Corbett, Executive Director and Chief Executive Officer	12,007,045 90.62%	0 0%	0 0%	1,243,405 9.38%	12,007,045 90.62%	0 0%	1,243,405 9.38%	Carried
Resolution 1: Election of Directors to serve a one-year term Jeremy Curnock Cook, Non-Executive Director	12,084,039 91.2%	0 0%	0 0%	1,165,850 8.8%	12,084,039 91.2%	0 0%	1,165,850 8.8%	Carried
Resolution 1: Election of Directors to serve a one-year term Professor Suzanne Crowe, Non-Executive Director	12,341,978 93.14%	0 0%	0 0%	908,472 6.86%	12,341,978 93.14%	0 0%	908,472 6.86%	Carried

Resolution 1: Election of Directors to serve a one-year term Jan Stern Reed, Non-Executive Director	11,611,092 87.65%	0 0%	0 0%	1,635,332 12.35%	11,611,092 87.65%	0 0%	1,635,332 12.35%	Carried
Resolution 1: Election of Directors to serve a one-year term Robert McNamara, Non-Executive Director	12,261,891 92.54%	0 0%	0 0%	988,559 7.46%	12,261,891 92.54%	0 0%	988,559 7.46%	Carried
Resolution 1: Election of Directors to serve a one-year term Cary Vance, Non-Executive Director	12,261,730 92.54%	0 0%	0 0%	988,720 7.46%	12,261,730 92.54%	0 0%	988,720 7.46%	Carried
Resolution 2: To ratify the appointment of Grant Thornton LLP as the Company's independent public accountants for the fiscal year ending December 31, 2024	14,794,234 96.28%	206,185 1.34%	0 0%	366,332 2.38%	14,794,234 96.28%	206,185 1.34%	366,332 2.38%	Carried
Resolution 3: To approve the grant of restricted stock units to acquire shares of Common Stock equal in value to \$87,500 (at the time of the grant) and the grant of options to acquire shares of Common Stock equal in value to \$37,500 (at the time of the grant) to Mr. Lou Panaccio on the terms and conditions set out in the Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11	10,834,366 81.91%	1,947,210 14.72%	0 0%	446,306 3.37%	10,834,366 81.91%	1,947,210 14.72%	446,306 3.37%	Carried
Resolution 4: To approve the grant of restricted stock units to acquire shares of Common Stock equal in value to \$87,500 (at the time of the grant) and the grant of options to acquire shares of Common Stock equal in value to \$37,500 (at the time of the grant) to Professor Suzanne Crowe on the terms and conditions set out in the Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11	10,848,440 82.01%	1,915,747 14.48%	0 0%	463,695 3.51%	10,848,440 82.01%	1,915,747 14.48%	463,695 3.51%	Carried

<p>Resolution 5:</p> <p>To approve the grant of restricted stock units to acquire shares of Common Stock equal in value to \$87,500 (at the time of the grant) and the grant of options to acquire shares of Common Stock equal in value to \$37,500 (at the time of the grant) to Mr. Jeremy Curnock Cook on the terms and conditions set out in the Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11</p>	<p>10,834,337 81.9%</p>	<p>1,948,061 14.73%</p>	<p>0 0%</p>	<p>445,484 3.37%</p>	<p>10,834,337 81.9%</p>	<p>1,948,061 14.73%</p>	<p>445,484 3.37%</p>	<p>Carried</p>
<p>Resolution 6:</p> <p>To approve the grant of restricted stock units to acquire shares of Common Stock equal in value to \$87,500 (at the time of the grant) and the grant of options to acquire shares of Common Stock equal in value to \$37,500 (at the time of the grant) to Ms. Jan Stern Reed on the terms and conditions set out in the Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11</p>	<p>10,696,549 80.86%</p>	<p>2,082,094 15.74%</p>	<p>0 0%</p>	<p>449,239 3.4%</p>	<p>10,696,549 80.86%</p>	<p>2,082,094 15.74%</p>	<p>449,239 3.4%</p>	<p>Carried</p>
<p>Resolution 7:</p> <p>To approve the grant of restricted stock units to acquire shares of Common Stock equal in value to \$87,500 (at the time of the grant) and the grant of options to acquire shares of Common Stock equal in value to \$37,500 (at the time of the grant) to Mr. Robert McNamara on the terms and conditions set out in the Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11</p>	<p>10,837,227 81.93%</p>	<p>1,935,886 14.63%</p>	<p>0 0%</p>	<p>454,769 3.44%</p>	<p>10,837,227 81.93%</p>	<p>1,935,886 14.63%</p>	<p>454,769 3.44%</p>	<p>Carried</p>
<p>Resolution 8:</p> <p>To approve the grant of restricted stock units to acquire shares of Common Stock equal in value to \$87,500 (at the time of the grant) and the grant of options to acquire shares of Common Stock equal in value to \$37,500 (at the time of the grant) to Mr. Cary Vance on the terms and conditions set out in the Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11</p>	<p>10,843,117 81.97%</p>	<p>1,935,084 14.63%</p>	<p>0 0%</p>	<p>449,681 3.4%</p>	<p>10,843,117 81.97%</p>	<p>1,935,084 14.63%</p>	<p>449,681 3.4%</p>	<p>Carried</p>

Resolution 9: To approve the grant of options to acquire 350,000 shares of Common Stock to the Company's Chief Executive Officer, Mr. James Corbett, on the terms and conditions set out in the Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11	10,040,922 75.91%	2,759,325 20.86%	0 0%	427,635 3.23%	10,040,922 75.91%	2,759,325 20.86%	427,635 3.23%	Carried
Resolution 10: Advisory vote to approve the compensation of the Company's named executive officers	10,269,125 77.63%	2,296,661 17.36%	0 0%	662,096 5.01%	10,269,125 77.63%	2,296,661 17.36%	662,096 5.01%	Carried

*Votes relating to a person who abstained on Resolution 1 or any of Resolutions 3 - 9 (as applicable) were not counted in determining whether or not the required majority of votes were cast for or against that Resolution. Votes relating to a person who abstained on Resolutions 2 or 10 (as applicable) were counted as votes "AGAINST" that Resolution in determining whether or not the required majority of votes were cast for or against that Resolution.